Inclusion Criteria:~1. Men, and women of non-childbearing potential, 50-85 years of age inclusively, with a
diagnosis of mild to moderate Alzheimer's disease according to the 2011 NIA-AA criteria and at least a 6 month
decline in cognitive function documented in the medical record.~ i) Non-childbearing potential for women is
defined as postmenopausal (last natural menses greater than 24 months) or undergone a documented bilateral
tubal ligation or hysterectomy. If last natural menses less than 24 months, a serum FSH value confirming
post-menopausal status can be employed.~ ii) Male participants who are sexually active with a woman of
child-bearing potential must agree to use condoms during the trial and for 3 months after last dose unless the
woman is using an acceptable means of birth control. Acceptable forms of birth control include abstinence,
birth control pills, or any double combination of: intrauterine device (IUD), male or female condom, diaphragm,
sponge, and cervical cap.~2. Diagnostic confirmation by amyloid PET with florbetaben or another approved
amyloid PET ligand. Previous amyloid imaging study with a positive result will be accepted. If none is
available, then amyloid PET will be conducted during screening. Diagnostic confirmation by a CSF sample
collected at the screening visit lumbar puncture in place of amyloid PET will also be acceptable~3.
Neuroimaging (MRI) obtained during screening consistent with the clinical diagnosis of Alzheimer's disease and
without findings of significant exclusionary abnormalities (see exclusion criteria, number 4). An historical
MRI, up to 1 year prior to screening, may be used as long as there is no history of intervening neurologic
disease or clinical events (such as a stroke, head trauma etc.) and the subject is without clinical symptoms or
signs suggestive of such intervening events.).~4. MMSE 18-26 inclusive.~
